Log in to save to my catalogue

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas...

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2787211719

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Anti-CD19 chimeric antigen receptor T cells (CART) has rapidly been adopted as the standard third-line therapy to treat aggressive B-cell lymphomas (ABCL) after failure of second-line therapy despite the lack of direct comparisons with allogeneic hematopoietic cell transplantation (alloHCT)-based strategies. Using the
Grupo Español de Trasplante...

Alternative Titles

Full title

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2787211719

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2787211719

Other Identifiers

ISSN

0268-3369

E-ISSN

1476-5365

DOI

10.1038/s41409-023-01949-x

How to access this item